Pegtarazimod improves oxygen use, inflammatory biomarkers in acute COPD exacerbation

ORLANDO — Among hospitalized adults with acute exacerbation of COPD, pegtarazimod improved oxygen utilization and inflammatory biomarkers, according to phase 2a data.These findings on pegtarazimod (RLS-0071), “a dual-acting, anti-inflammatory peptide that inhibits the classical pathway of complement and neutrophil inflammatory effectors myeloperoxidase (MPO) and neutrophil